Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Cross Below Two Hundred Day Moving Average – Time to Sell?

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $30.95 and traded as low as $29.19. Lakefront Biotherapeutics American Depositary Shares shares last traded at $29.67, with a volume of 122,618 shares traded.

Analyst Ratings Changes

LKFT has been the topic of a number of recent analyst reports. Wall Street Zen lowered shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Zacks Research upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research note on Monday, June 8th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $36.50.

Lakefront Biotherapeutics American Depositary Shares Stock Down 1.3%

The stock has a 50-day moving average of $28.21 and a 200 day moving average of $30.94. The stock has a market cap of $1.95 billion, a PE ratio of -20.99 and a beta of 0.26.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last posted its quarterly earnings results on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share (EPS) for the quarter. The business had revenue of $1.06 billion for the quarter. On average, equities analysts anticipate that Lakefront Biotherapeutics American Depositary Shares will post -6.32 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Western Standard LLC acquired a new stake in Lakefront Biotherapeutics American Depositary Shares during the 4th quarter worth about $1,046,000. UBS Group AG lifted its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 128.4% in the 4th quarter. UBS Group AG now owns 349,444 shares of the biotechnology company’s stock valued at $11,427,000 after buying an additional 196,445 shares during the period. Barometer Capital Management Inc. lifted its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 63.2% in the 3rd quarter. Barometer Capital Management Inc. now owns 27,617 shares of the biotechnology company’s stock valued at $957,000 after buying an additional 10,700 shares during the period. Geode Capital Management LLC purchased a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the second quarter worth about $220,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the third quarter worth about $211,000. 32.46% of the stock is currently owned by institutional investors and hedge funds.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.